DKC1 and colorectal carcinoma: Notably, Pyrazofurin, when combined with trametinib (a MAP kinase inhibitor), effectively inhibits the growth of CRC cells with elevated DKC1 expression in vitro and in vivo, suggesting potential applications in DKC1‐overexpressing cancers.112